Objectives: To determine the efficacy of cell culture based influenza vaccines in children. Methods: Embase, PubMed, Cochrane and clinical trials were searched.14 randomised controlled trials in children were selected. The current systematic review was done as per the PRISMA guidelines. The pooled estimate of seroconversion and GMT rate was calculated as mean difference. Data was analysed using the Cochrane Collaboration Review Manager Version software. Risk of bias was done as per Cochrane risk of bias tool. The quality of evidence was adjudged using Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) using the Grade pro software. Results: Significant results for efficacy were reported for half dose MF59 influenza vaccine control group for GMT at day 1 with a mean difference of 0.78, 95%CI, 0.50 to 1.07, p<0.00001 as compared to full dose MF59 influenza vaccine experimental group .No significant results were reported in half dose MF59 influenza vaccine for GMT at Day 43(mean difference 151.57,95% CI,-29.36 to 332.50 ,p=0.10). Significant results were reported for seroconversion rate for half dose MF59 influenza vaccine control group at day 22 with a mean difference of 17.92,95%CI,10.08 to 25.75,p<0.00001 as compared to half dose MF59 influenza vaccine group at day 43 with a mean difference of 5.00,95%CI,-4.80 to 14.80,p=0.32 . Conclusion: The current systematic review demonstrated that half dose cell derived influenza vaccines was well tolerated and more immunogenic and resulted in high seroconversion rate and Geometric Mean Titres rate in paediatric population.